Pamlico Biopharma raises $2.2 mln
AcceleVenture Partners has led a $2.2 million round for Pamlico Biopharma Inc. I2E Inc. which made the investment through the Oklahoma Seed Capital Fund which it manages, also participated. Oklahoma City-based Pamlico BioPharma, a portfolio company of Accele Biopharma, is a biopharmaceutical company that focuses on human monoclonal antibody therapeutics for infectious disease and cancer. Accele Venture Partners is also the investing arm of Accele Biopharma.
30 April 2015•3 mins read
